JFL Life Sciences Limited has announced the convening of its 16th Annual General Meeting (AGM) on Tuesday, August 25, 2026, at 2:00 P.M. (IST), to be held through Video Conferencing (VC)/Other Audio-Visual Means (OAVM) in compliance with applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. The notice was filed with the National Stock Exchange of India Limited on July 31, 2026, along with the company's Integrated Annual Report for the financial year 2025-26.

AGM Agenda at a Glance

The 16th AGM will transact both ordinary and special business. The following table summarises the key agenda items:

E-Voting and Record Date

Members eligible to participate in remote e-voting are those whose names appear in the Register of Members/Beneficial Owners as on the record date of Wednesday, August 19, 2026. The remote e-voting window opens on Saturday, August 22, 2026, at 09:00 A.M. and closes on Monday, August 24, 2026, at 05:00 P.M. The e-voting facility is being provided through National Securities Depository Limited (NSDL).

Financial Performance for FY2025-26

The company's Board of Directors presented the following financial highlights for the year ended March 31, 2026. All figures are in Lakhs.

The company reported a turnover of ₹13,138.26 lakhs and a net profit of ₹640.10 lakhs for FY2025-26. The Board has not recommended any dividend for the financial year, citing future growth and expansion requirements. The entire net profit has been transferred to reserves.

Key Financial Ratios

The following key financial ratios were reported for the periods ended March 31, 2026 and March 31, 2025:

Director Reappointments: Key Details

The Board, at its meeting held on July 31, 2026, approved the following reappointments, subject to shareholder approval at the 16th AGM:

• Mr. Smiral Ashwinkumar Patel (DIN: 00769486) — Reappointment as Managing Director for a period of five consecutive years commencing January 18, 2027 and ending January 17, 2032. Remuneration sought: ₹24,00,000/- p.a.
• Mrs. Tejal Smiral Patel (DIN: 07391559) — Reappointment as Whole Time Director for five consecutive years commencing January 18, 2027 and ending January 17, 2032. Remuneration sought: ₹15,00,000/- p.a.
• Ms. Sonu Lalitkumar Jain (DIN: 09387661) — Reappointment as Non-Executive Independent Director for a second consecutive term of five years commencing January 18, 2027 and ending January 17, 2032. Sitting fees: ₹5,000/- per meeting, subject to a maximum of ₹75,000/-.
• Ms. Bhavna Basantbhai Shah (DIN: 09494548) — Reappointment as Non-Executive Independent Director for a second consecutive term of five years commencing February 10, 2027 and ending February 9, 2032. Sitting fees: ₹5,000/- per meeting, subject to a maximum of ₹75,000/-.

Share Capital and CSR

The authorized share capital of the company as on March 31, 2026 stands at ₹67,50,00,000, while the issued, subscribed and paid-up capital is ₹32,99,53,230. All 3,29,95,323 equity shares (100%) are held in demat form as on March 31, 2026. During the year, the Board approved a rights issue of 3,29,95,323 fully paid-up equity shares of face value ₹10/- each at an issue price of ₹10/- per share, aggregating to ₹3,299.53 Lakhs; however, the rights issue did not receive the minimum subscription amount and was treated as devolved, with no equity shares allotted pursuant to the said rights issue.

On the CSR front, the company was required to spend ₹9,10,314/- (being 2% of average net profit of ₹4,55,15,667/-) during FY2025-26. The company incurred CSR expenditure of ₹10,00,000/- during the year, resulting in an excess spend of ₹89,686/-.

JFL Life Sciences disclosed that its promoters and promoter group have not created any encumbrance on their shares during the financial year 2025-2026. The confirmation was submitted to the National Stock Exchange on April 04, 2025, in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The disclosure ensures transparency regarding the shareholding status of the key stakeholders.

The letter, addressed to the Manager of the Listing Department at the National Stock Exchange of India Limited, was signed by Smiral Ashwinkumar Patel on behalf of the promoter and promoter group. It explicitly states that no encumbrance was made directly or indirectly, other than those already disclosed.

Promoter and Promoter Group Details

The disclosure identified the individuals comprising the promoter and promoter group of JFL Life Sciences.

The filing confirms adherence to the regulatory requirements aimed at monitoring the pledging or encumbrance of shares by promoters.